Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimura + Lucentis in Wet AMD
NCT03362190Phase 2Completed
- Sponsor
- IVERIC bio
- Start
- Oct 2017
- Primary completion
- Oct 2018
- Modality
- RNA Aptamers, DNA Aptamers
- Countries
- 3
01
Overview
A Phase 2 trial of avacincaptad pegol in neovascular age-related macular degeneration (NVAMD), sponsored by IVERIC bio. Started Oct 2017; status: completed.
02
Drugs
avacincaptad pegol
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03362190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03362190.